Precigen (PGEN) Q3 2025 earnings summary

Executive summary

• Achieved full FDA approval and US commercial launch of PAPZIMEOS for adults with RRP in August 2025, marking the first and only approved therapy for this indication and a transition to commercial stage, with rapid adoption and over 100 patients registered.

• Broad label approval allows use in all adult RRP patients, regardless of disease severity or prior surgeries.

• Strategic pipeline prioritization in 2024 led to shutdown of ActoBio subsidiary, workforce reduction, and focus on PAPZIMEOS commercialization.

• Realigned to a single operating segment in 2025 to streamline operations and focus on core business.

• Submitted Marketing Authorization Application to the EMA for PAPZIMEOS in November 2025, expanding geographic reach.

Financial highlights

• Ended Q3 2025 with $123.6 million in cash, cash equivalents, and investments, following a drawdown of the first tranche of a new credit facility.

• Total revenues for Q3 2025 were $2.9 million, up over 200% year-over-year, driven by $1.8 million in collaboration/licensing revenue from termination of an agreement with PTC Therapeutics.

• Net loss attributable to common shareholders for Q3 2025 was $325.3 million ($1.06 per share), mainly due to non-cash items including a $179 million non-cash deemed dividend and $111.5 million warrant liability change.

• SG&A expenses increased by $14.2 million (144%) year-over-year, primarily due to commercialization costs and share-based awards.

• Inventory at quarter-end was approximately $3 million, reflecting post-approval manufacturing costs.

Outlook and guidance

• Cash and projected PAPZIMEOS revenues are expected to fund operations to cash breakeven, with breakeven targeted by end of 2026.

• Gross-to-net revenue adjustment anticipated in the high teens to low 20% range, consistent with industry peers.

• Ongoing investments in infrastructure, including a new ERP system, position the company for commercial operations.

• Management expects future revenues to be driven by PAPZIMEOS commercialization; collaboration revenue to remain minimal unless new agreements are executed.

• Future capital needs will depend on commercial success of PAPZIMEOS, R&D progress, and potential strategic transactions.